首页|甲泼尼龙琥珀酸钠联合巴曲酶治疗突发性耳聋的临床研究

甲泼尼龙琥珀酸钠联合巴曲酶治疗突发性耳聋的临床研究

Clinical study on methylprednisolone sodium succinate combined with batroxobin for treatment of sudden deafness

扫码查看
目的 分析注射用甲泼尼龙琥珀酸钠联合巴曲酶注射液对突发性耳聋的治疗效果.方法 研究对象为金华市妇幼保健院耳鼻咽喉科收治的90例突发性耳聋患者,所有患者均于2022年6月至2023年6月入院,以奇偶数抽签法将其分为对照组45例行注射用甲泼尼龙琥珀酸钠治疗,观察组45例行注射用甲泼尼龙琥珀酸钠+巴曲酶注射液,治疗2周后,对比两组治疗效果与不良反应.结果 观察组治疗有效率95.56%高于对照组73.33%,差异具有统计学意义(χ2=8.459,P<0.05);治疗后,观察组纯音听阈值(32.46±4.11)dB、听觉诱发电位(51.28±5.49)dB、听觉脑干反应(3.55±1.24)ms均低于对照组(37.15±4.68)dB、(59.64±6.05)dB、(5.03±1.86)ms,差异具有统计学意义(均P<0.05);治疗后,观察组血浆黏度(1.28±0.16)mPa·s-1、纤维蛋白原(2.54±1.05)g·L-1低于对照组(1.61±0.22)mPa·s-1、(3.07±1.10)g·L-1,差异具有统计学意义(均P<0.05);治疗后,观察组内皮素1[(1.34±0.11)pg·mL-1]、可溶性血管细胞黏附分子-1[(216.25±45.15)μg·L-1]、同型半胱氨酸[(8.18±2.56)μmol·L-1]和白细胞介素-6[(15.58±2.24)pg·mL-1]、白细胞介素-10[(6.58±1.54)pg·L-1]、C反应蛋白[(7.71±1.20)mg·L-1]均低于对照组[(1.78±0.23)pg·mL-1、(267.28±51.42)μg·L-1、(11.65±2.35)μmol·L-1、(19.54±3.12)pg·mL-1、(9.24±1.87)pg·L-1、(9.85±1.37)mg·L-1],差异具有统计学意义(均P<0.05);两组不良反应发生率差异无统计学意义(χ2=2.195,P=0.138).结论 对突发性耳聋患者行注射用甲泼尼龙琥珀酸钠联合巴曲酶治疗能够有效改善血液流变学及血管内皮功能,降低炎症反应,从而恢复听力水平,疗效显著.
Objective To analyze curative efficacy of methylprednisolone sodium succinate injection combined with batroxo-bin injection in treating sudden deafness.Methods According to odd-even picking method,90 patients with sudden deafness ad-mitted to Jinhua Maternal and Child Health Hospital from June 2022 to June 2023 were enrolled in this study and divided into the control group(n=45,treated with methylprednisolone sodium succinate injection)and observation group(n=45,treated with methyl-prednisolone sodium succinate injection combined with batroxobin injection).After 2 weeks of treatment,curative efficacy and ad-verse reactions were compared between the two groups.Results The response rate of treatment was higher in the observation group than in the control(95.56%vs 73.33%),and the difference was statistically significant(χ2=8.459,P<0.05).After treatment,pure tone average value,auditory evoked potential and auditory brainstem response time in the observation group were significantly lower than those in the control((32.46±4.11)dB vs(37.15±4.68)dB,(51.28±5.49)dB vs(59.64±6.05)dB,(3.55±1.24)ms vs(5.03±1.86)ms,P<0.05).The levels of plasma viscosity and fibrinogen(FIB)in the observation group were remarkably lower than those in the control((1.28±0.16)mPa·s-1 vs(1.61±0.22)mPa·s-1,(2.54±1.05)g·L-1 vs(3.07±1.10)g·L-1,P<0.05).The levels of endothelin-1,soluble vascular cell adhesion molecule-1,homocysteine,interleukin-6,interleukin-10 and C-reactive protein in the observation group were also signifi-cantly lower than those in the control((1.34±0.11)pg·mL-1 vs(1.78±0.23)pg·mL-1,(216.25±45.15)μg·L-1 vs(267.28±51.42)μg·L-1,(8.18±2.56)μmol·L-1 vs(11.65±2.35)μmol·L-1,(15.58±2.24)pg·mL-1 vs(19.54±3.12)pg·mL-1,(6.58±1.54)pg·L-1 vs(9.24±1.87)pg·L-1,(7.71±1.20)mg·L-1 vs(9.85±1.37)mg·L-1,P<0.05).The difference in the incidence of adverse reactions was not statistically signif-icant between the two groups(χ2=2.195,P=0.138).Conclusion Methylprednisolone sodium succinate combined with batroxobin can effectively improve hemorheology and vascular endothelial function,reduce inflammatory response and thus recover hearing lev-el in patients with sudden deafness.Meanwhile,it has significant curative efficacy for this disease.

Sudden deafnessMethylprednisolone sodium succinateBatroxobinHearingInflammatory factor

吕嘉雯、黄浦城、马淑婷、王榴倩

展开 >

金华市妇幼保健院耳鼻咽喉科,金华 321000

金华市中心医院耳鼻咽喉外科,金华 321000

突发性耳聋 注射用甲泼尼龙琥珀酸钠 巴曲酶 听力 炎症因子

2024

中国药物应用与监测
中国人民解放军总医院

中国药物应用与监测

CSTPCD
影响因子:1.983
ISSN:1672-8157
年,卷(期):2024.21(5)